{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:41:52Z","timestamp":1792456912556,"version":"4.5.0"},"reference-count":38,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2009,3,12]],"date-time":"2009-03-12T00:00:00Z","timestamp":1236816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2009,7]]},"abstract":"<jats:p>Gain\u2010of\u2010function mutations of the receptor tyrosine kinase KIT can cause systemic mastocytosis (SM) and gastrointestinal stromal tumors. Most of the constitutively active KIT can be inhibited by imatinib; D816V KIT cannot. In this study, we investigated the activity of triptolide, a diterpenoid isolated from the Chinese herb <jats:italic>Tripterygium wilfordii <\/jats:italic>Hook. f., in cells expressing mutant KIT, including D816V KIT. Imatinib\u2010sensitive HMC\u20101.1 cells harboring the mutation V560G in the juxtamembrane domain of KIT, imatinib\u2010resistant HMC\u20101.2 cells harboring both V560G and D816V mutations, and murine P815 cells, were treated with triptolide, and analyzed in terms of growth, apoptosis, and signal transduction. The <jats:italic>in vivo<\/jats:italic> antitumor activity was evaluated by using the nude mouse xenograft model. Our results demonstrated that triptolide potently inhibits the growth of both human and murine mast cells harboring not only imatinib\u2010sensitive KIT mutation but also imatinib\u2010resistant D816V KIT. Triptolide markedly inhibited KIT mRNA levels and strikingly reduced the levels of phosphorylated and total Stat3, Akt, and Erk1\/2, downstream targets of KIT. Triptolide triggered apoptosis by inducing depolarization of mitochondrial potential and release of cytochrome c, downregulation of Mcl\u20101 and XIAP. Furthermore, triptolide significantly abrogated the growth of imatinib\u2010resistant HMC\u20101.2 cell xenografts in nude mice and decreased KIT expression in xenografts. Our data demonstrate that triptolide inhibits imatinib\u2010resistant mast cells harboring D816V KIT. Further investigation of triptolide for treatment of human neoplasms driven by gain\u2010of\u2010function KIT mutations is warranted. (<jats:italic>Cancer Sci<\/jats:italic> 2009; 100: 1335\u20131343)<\/jats:p>","DOI":"10.1111\/j.1349-7006.2009.01159.x","type":"journal-article","created":{"date-parts":[[2009,3,12]],"date-time":"2009-03-12T09:51:27Z","timestamp":1236851487000},"page":"1335-1343","source":"Crossref","is-referenced-by-count":23,"title":["Activity of triptolide against human mast cells harboring the kinase domain mutant KIT"],"prefix":"10.1111","volume":"100","author":[{"given":"Yanli","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianping","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongzheng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingrong","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxuan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,6,10]]},"reference":[{"key":"e_1_2_7_2_2","first-page":"197","article-title":"Systemic mastocytosis: current concepts and treatment advances","volume":"3","author":"Tefferi A","year":"2004","journal-title":"Curr Hematol Rep"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4771"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22187"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1159\/000085561"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190400010775"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.279.5350.577"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-472X(03)00112-7"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116761"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-3022"},{"key":"e_1_2_7_11_2","first-page":"1115","article-title":"Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild\u2010type c\u2010kit whereas the kinase domain mutant D816VKit is resistant","volume":"1","author":"Frost MJ","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.5.1741"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.4.1609"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-3969"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gde.2006.12.010"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2933"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1155\/SRCM\/2006\/64374"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.08.021"},{"key":"e_1_2_7_19_2","first-page":"327","article-title":"A prospective, controlled, double\u2010blind, cross\u2010over study of tripterygium wilfodii hook F in treatment of rheumatoid arthritis","volume":"102","author":"Tao XL","year":"1989","journal-title":"Chin Med J (Engl)"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00866356"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja00775a078"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199801)41:1<130::AID-ART16>3.0.CO;2-4"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204981"},{"key":"e_1_2_7_24_2","first-page":"855","article-title":"PG490\u201388, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy","volume":"2","author":"Fidler JM","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2007.07.001"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-857X(05)70118-6"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.2165\/00126839-200304010-00001"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-6207"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(88)90050-1"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.9.2619.2619"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.5.2.2316"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-013805"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404714"},{"key":"e_1_2_7_34_2","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.1210\/jcem.86.10.7860","article-title":"Cytochrome c release is upstream to activation of caspase\u20109, caspase\u20108, and caspase\u20103 in the enhanced apoptosis of anaplastic thyroid cancer cells induced by manumycin and paclitaxel","volume":"86","author":"Pan J","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2005.06.033"},{"key":"e_1_2_7_36_2","first-page":"65","article-title":"Triptolide inhibits the growth and metastasis of solid tumors","volume":"2","author":"Yang S","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3898"},{"key":"e_1_2_7_38_2","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1182\/blood-2006-07-032714","article-title":"Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412","volume":"109","author":"Aichberger KJ","year":"2007","journal-title":"Blood"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2141"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1349-7006.2009.01159.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1349-7006.2009.01159.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T08:10:59Z","timestamp":1697184659000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1349-7006.2009.01159.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,10]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["10.1111\/j.1349-7006.2009.01159.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1349-7006.2009.01159.x","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,10]]}}}